MedTrace Logo

Clinical Epidemiology in Contemporary Patients With Myelofibrosis.

NCT06533813 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 617

Last updated 2025-12-26

No results posted yet for this study

Summary

Multicenter retrospective and prospective European observational study. At each site, all consecutive patients with a 2016- or 2022 World Health Organization (WHO) confirmed diagnosis of myelofibrosis (MF) established from 01/01/2018 to 31/12/2027 will be enrolled into the study. Yearly follow-up updates will be scheduled until the end of data collection on 31/12/2028 or until the last available patient visit, whichever comes first. At least 1 year of follow-up will be ensured from the last patient enrolled.

Conditions

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS

    lead OTHER

Principal Investigators

  • TIZIANO BARBUI, MD · FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-14
Primary Completion
2025-12-19
Completion
2028-12-31

Countries

  • Armenia
  • Denmark
  • France
  • Germany
  • Israel
  • Italy
  • Moldova
  • Poland
  • Romania
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06533813 on ClinicalTrials.gov